This once-hot cancer-detection company’s stock got cut in half after a failed trial

1 hour ago 5

Grail’s stock was the Nasdaq’s biggest loser Friday, after a key trial of its Galleri early-detection cancer test failed to meet its primary endpoint.

Read Entire Article

This once-hot cancer-detection company’s stock got cut in half after a failed trial

Related

Ethereum Hits Multi-Year Accumulation High While Price Actio...

CZ Returns to US for Trump-Backed Crypto Event

SEC makes quiet shift to brokers' stablecoin holdings that m...

Trending

Popular

Bond investors should worry less about Treasury yields, and ...

Why the dollar just had its worst week in 8 months despite T...

Here’s why bitcoin’s is failing its role as a 'safe haven' v...

Thailand plans crypto ETF rules as institutional interest in...

Why AMD’s stock is charging higher as Intel’s sinks

Coinbase VP says ‘fatal flaws’ in Senate crypto bill forced ...

‘Literally billions’ of AI agents to use stablecoins in 5 ye...

Will XRP price double again? 'Latent' buy pressure puts shor...

Bitcoin payments held back by tax policy, not scaling tech: ...

Former Alameda CEO to be released from US custody after 440 ...